Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373045 · ClinicalTrials.gov registry record
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
A clinical trial of Asthma, sponsored by AstraZeneca.
- Completed
- Registry status
- 18
- Enrollment target
- 20
- Study locations
NCT03373045: Completed study of Asthma, sponsored by AstraZeneca.
NCT03373045 is a study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 18 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03373045, a study of Asthma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
- 20
- Study locations
Study Summary
The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose inhaled corticosteroid (ICS) therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. Data will be collected from the healthcare provider in a uniform manner for every patient enrolled using an electronic case report form (eCRF). Data will be collected monthly from patients via web-based surveys. Patients will be followed until study discontinuation or the patient withdraws from the study or death, whichever occurs first. The expectation is that patients will be followed for a period of at least 3 years.
Primary Outcome
Longitudinal changes of Healthcare utilization will be measured using directly collected information from medical, hospital, and pharmacy records to provide a supplementary comprehensive assessment of each patient's healthcare utilization during the study period.
Conditions Studied
Study Locations (20)
California
- Research Site - Bakersfield
- Research Site - Loma Linda
- Research Site - Los Angeles
- Research Site - Mission Viejo
- Research Site - Modesto
- Research Site - Redondo Beach
- Research Site - Riverside
- Research Site - Roseville
- Research Site - Sacramento
- Research Site - San Diego
- Research Site - San Diego
- Research Site - San Diego
- Research Site - Santa Monica
- Research Site - Studio City
Alabama
- Research Site - Birmingham
- Research Site - Birmingham
- Research Site - Hoover
Arizona
- Research Site - Gilbert
- Research Site - Peoria
Arkansas
- Research Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2025-02-14 |
What the finished NCT03373045 record still lists
NCT03373045 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 0 interventions.
NCT03373045 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT03373045 about?
NCT03373045 is a clinical study titled "Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)". The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose inhaled corticosteroid (ICS) therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. Data will...
What is the current status of trial NCT03373045?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2018-02-27. Estimated completion is 2025-02-14.
What conditions does trial NCT03373045 study?
This clinical trial studies the following conditions: Asthma.
Who is sponsoring clinical trial NCT03373045?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03373045 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03373045's enrollment target sits among peer trials
18 347th of 374 higher than 27 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI